Lilly claims promising finding in failed study of COVID-19 drug

Treatment with a repurposed arthritis drug from Eli Lilly and Incyte did not significantly lessen the risk of worsening disease among people hospitalized with COVID-19, the company announced Thursday, citing results from an international study of some 1,500 volunteers.